JPH029009B2 - - Google Patents
Info
- Publication number
- JPH029009B2 JPH029009B2 JP57178243A JP17824382A JPH029009B2 JP H029009 B2 JPH029009 B2 JP H029009B2 JP 57178243 A JP57178243 A JP 57178243A JP 17824382 A JP17824382 A JP 17824382A JP H029009 B2 JPH029009 B2 JP H029009B2
- Authority
- JP
- Japan
- Prior art keywords
- methotrexate
- lens
- antimitotic agent
- eye
- retinoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003080 antimitotic agent Substances 0.000 claims description 21
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 20
- 229960000485 methotrexate Drugs 0.000 claims description 20
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 16
- 229930002330 retinoic acid Natural products 0.000 claims description 16
- 229960001727 tretinoin Drugs 0.000 claims description 16
- 210000002919 epithelial cell Anatomy 0.000 claims description 15
- 210000002159 anterior chamber Anatomy 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000000394 mitotic effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000695 crystalline len Anatomy 0.000 description 37
- 239000002775 capsule Substances 0.000 description 24
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 20
- 208000002177 Cataract Diseases 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229960001338 colchicine Drugs 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000001542 lens epithelial cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000008516 Capsule Opacification Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940088319 miostat Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229920003319 Araldite® Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100001097 no ocular toxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N5/00—Details of television systems
- H04N5/14—Picture signal circuitry for video frequency region
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N5/00—Details of television systems
- H04N5/14—Picture signal circuitry for video frequency region
- H04N5/20—Circuitry for controlling amplitude response
- H04N5/205—Circuitry for controlling amplitude response for correcting amplitude versus frequency characteristic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Multimedia (AREA)
- Signal Processing (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Picture Signal Circuits (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Networks Using Active Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/310,139 US4399460A (en) | 1981-10-09 | 1981-10-09 | Video signal peaking control system with provision for automatic and manual control |
| US310159 | 1981-10-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5874609A JPS5874609A (ja) | 1983-05-06 |
| JPH029009B2 true JPH029009B2 (en]) | 1990-02-28 |
Family
ID=23201163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57178232A Granted JPS5873289A (ja) | 1981-10-09 | 1982-10-08 | 映像信号の高周波ピーキング成分を自動および手動で制御する装置 |
| JP57178243A Granted JPS5874609A (ja) | 1981-10-09 | 1982-10-09 | のう外摘出後における水晶体の残遺部上皮細胞の増殖を防止するための有糸分裂阻止剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57178232A Granted JPS5873289A (ja) | 1981-10-09 | 1982-10-08 | 映像信号の高周波ピーキング成分を自動および手動で制御する装置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4399460A (en]) |
| JP (2) | JPS5873289A (en]) |
| KR (1) | KR920000573B1 (en]) |
| AT (1) | AT385619B (en]) |
| AU (1) | AU558172B2 (en]) |
| CA (1) | CA1185354A (en]) |
| DE (1) | DE3237421C2 (en]) |
| ES (1) | ES8401701A1 (en]) |
| FR (1) | FR2514598B1 (en]) |
| GB (1) | GB2107552B (en]) |
| IT (1) | IT1152706B (en]) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4509080A (en) * | 1982-07-02 | 1985-04-02 | Rca Corporation | Video signal peaking system |
| GB2118396B (en) * | 1982-03-31 | 1985-09-25 | Rca Corp | Video signal peaking system |
| GB2118007B (en) * | 1982-03-31 | 1985-11-13 | Rca Corp | Adjustable coring circuit |
| US4437124A (en) * | 1982-04-30 | 1984-03-13 | Rca Corporation | Dynamic coring circuit |
| US4538236A (en) * | 1982-09-24 | 1985-08-27 | Rca Corporation | Adaptive digital signal coring circuit |
| US4536796A (en) * | 1983-08-23 | 1985-08-20 | Rca Corporation | Non-linear dynamic coring circuit for video signals |
| US4680631A (en) * | 1984-09-19 | 1987-07-14 | Tokyo Electric Co., Ltd. | Television composite video signal processing circuit |
| US4635118A (en) * | 1985-01-28 | 1987-01-06 | Rca Corporation | Interface circuit for video signal peaking control |
| US4623924A (en) * | 1985-02-19 | 1986-11-18 | Rca Corporation | Video signal auto peaking circuitry |
| US4918165A (en) * | 1987-07-16 | 1990-04-17 | Ophthalmic Research Corporation | Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction |
| KR950003021B1 (ko) * | 1989-06-26 | 1995-03-29 | 주식회사 금성사 | 브이씨알의 리모콘에 의한 해상도 업/다운 회로 및 그 제어방법 |
| US5121209A (en) * | 1990-10-01 | 1992-06-09 | Rca Licensing Corporation | Sharpness control for a television image |
| US5299000A (en) * | 1992-06-17 | 1994-03-29 | Zenith Electronics Corp. | Video white signal compression and peaking |
| EP0969657A1 (en) * | 1998-06-29 | 2000-01-05 | NuWave Technologies, Inc. | Apparent image clarity improving apparatus and method |
| SG115542A1 (en) * | 2003-05-21 | 2005-10-28 | St Microelectronics Asia | Adaptive coring for video peaking |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2629706C3 (de) * | 1976-07-02 | 1986-07-10 | Robert Bosch Gmbh, 7000 Stuttgart | Verfahren zur Übertragung und/oder Aufzeichnung von Farbfernsehsignalen |
| US4075661A (en) * | 1976-08-19 | 1978-02-21 | The Magnavox Company | Automatic peaking circuit |
| US4090217A (en) * | 1976-08-23 | 1978-05-16 | Gte Laboratories Incorporated | Automatic sharpness control circuit for a television receiver |
| US4081836A (en) * | 1976-11-30 | 1978-03-28 | The Magnavox Company | Luminance signal processor for providing signal enhancement |
| US4069505A (en) * | 1977-01-19 | 1978-01-17 | Gte Sylvania Incorporated | Automatic peaking control circuitry for a video processing system |
| US4296435A (en) * | 1980-08-18 | 1981-10-20 | Zenith Radio Corporation | Luminance signal processing circuit |
| US4351003A (en) * | 1981-04-20 | 1982-09-21 | Rca Corporation | Automatic video signal peaking control |
-
1981
- 1981-10-09 US US06/310,139 patent/US4399460A/en not_active Expired - Lifetime
-
1982
- 1982-10-01 ES ES516147A patent/ES8401701A1/es not_active Expired
- 1982-10-01 AU AU88962/82A patent/AU558172B2/en not_active Ceased
- 1982-10-05 GB GB08228457A patent/GB2107552B/en not_active Expired
- 1982-10-06 IT IT23642/82A patent/IT1152706B/it active
- 1982-10-07 CA CA000413029A patent/CA1185354A/en not_active Expired
- 1982-10-08 FR FR8216920A patent/FR2514598B1/fr not_active Expired
- 1982-10-08 DE DE3237421A patent/DE3237421C2/de not_active Expired
- 1982-10-08 JP JP57178232A patent/JPS5873289A/ja active Granted
- 1982-10-08 KR KR8204551A patent/KR920000573B1/ko not_active Expired
- 1982-10-09 JP JP57178243A patent/JPS5874609A/ja active Granted
- 1982-10-11 AT AT0375382A patent/AT385619B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT8223642A0 (it) | 1982-10-06 |
| JPH0134501B2 (en]) | 1989-07-19 |
| AU8896282A (en) | 1983-04-14 |
| DE3237421C2 (de) | 1986-09-11 |
| GB2107552B (en) | 1985-06-12 |
| KR840002197A (ko) | 1984-06-11 |
| JPS5873289A (ja) | 1983-05-02 |
| AT385619B (de) | 1988-04-25 |
| KR920000573B1 (ko) | 1992-01-16 |
| GB2107552A (en) | 1983-04-27 |
| FR2514598A1 (fr) | 1983-04-15 |
| IT1152706B (it) | 1987-01-07 |
| ATA375382A (de) | 1987-09-15 |
| AU558172B2 (en) | 1987-01-22 |
| JPS5874609A (ja) | 1983-05-06 |
| ES516147A0 (es) | 1983-12-16 |
| FR2514598B1 (fr) | 1988-03-11 |
| US4399460A (en) | 1983-08-16 |
| DE3237421A1 (de) | 1983-04-21 |
| ES8401701A1 (es) | 1983-12-16 |
| CA1185354A (en) | 1985-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1148880B1 (en) | Methods for restoring and/or enhancing accommodation in pseudo phakia | |
| Haus et al. | Mitomycin against posterior capsular opacification: an experimental study in rabbits. | |
| US4515794A (en) | Mitotic inhibitors preventing posterior lens capsule opacification | |
| JPH029009B2 (en]) | ||
| US4657930A (en) | Mitotic inhibitors preventing posterior lens capsule opacification | |
| EP0077197B1 (en) | Use of methotrexate and/or retinoic acid for the manufacture of compositions for use in preventing proliferation of remnant lens epithelial cells after extracapsular extraction | |
| Hunkeler et al. | The triple procedure: combined penetrating keratoplasty, cataract extraction and lens implantation | |
| RU2187984C2 (ru) | Способ лечения воспалительных заболеваний глаза | |
| Peyman et al. | Ultraviolet light absorbing pseudophakos | |
| RU2513997C1 (ru) | Комбинированный офтальмологический препарат в виде глазных капель, содержащий полигексаметиленгуанидин и таурин | |
| Kraff et al. | Membrane formation after implantation of polyvinyl alcohol-coated intraocular lenses | |
| RU2730975C1 (ru) | Способ лечения эндотелиально-эпителиальной дистрофии роговицы | |
| Legler et al. | Comments on silicone intraocular lens discoloration | |
| Ohguro et al. | The effects of denatured sodium hyaluronate on the corneal endothelium in cats | |
| CA2436397A1 (en) | Method of treating certain eye diseases | |
| JPH08175984A (ja) | 後発白内障予防剤 | |
| Kline et al. | Effect of BSS Plus on the corneal endothelium with intraocular lens implantation | |
| RU2135127C1 (ru) | Раствор для защиты и лечения заболеваний и повреждений роговицы "визитин" | |
| Thorpe | Enzymatic Zonulolysis: Alpha Chymotrypsin‐an Aid to Intracapsular Cataract Extraction | |
| CN102349901A (zh) | 吡非尼酮在制备防治眼科手术后增殖性疾病的药物中的应用及其滴眼液 | |
| McLEAN | Lens and vitreous | |
| JPH08325143A (ja) | 角膜実質損傷治療剤 | |
| JPH0236128A (ja) | 眼内注射剤 | |
| Wallar et al. | Posterior capsulotomy | |
| RU2193375C2 (ru) | Способ защиты внутренних структур глаза от ультразвукового воздействия при факоэмульсификации |